Apr 25, 2024 • 7:30 AM EDT XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
Upcoming Event May 15, 2024 • 9:00 am EDT 2024 Annual Meeting of Stockholders View Event Add to Calendar View All